Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | apurinic/apyrimidinic endonuclease, putative | 0.0015 | 0.1934 | 0.1934 |
Brugia malayi | ImpB/MucB/SamB family protein | 0.002 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.002 | 1 | 1 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.002 | 1 | 1 |
Leishmania major | DNA polymerase kappa, putative | 0.002 | 1 | 1 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.002 | 1 | 1 |
Giardia lamblia | DINP protein human, muc B family | 0.002 | 1 | 1 |
Leishmania major | DNA polymerase kappa, putative,DNA polymerase IV, putative | 0.002 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.002 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.002 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.002 | 1 | 1 |
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.002 | 1 | 1 |
Treponema pallidum | exodeoxyribonuclease (exoA) | 0.0015 | 0.1934 | 0.5 |
Loa Loa (eye worm) | ImpB/MucB/SamB family protein | 0.002 | 1 | 1 |
Mycobacterium tuberculosis | Possible DNA-damage-inducible protein P DinP (DNA polymerase V) (pol IV 2) (DNA nucleotidyltransferase (DNA-directed)) | 0.002 | 1 | 1 |
Plasmodium vivax | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0015 | 0.1934 | 0.5 |
Trichomonas vaginalis | DNA polymerase eta, putative | 0.002 | 1 | 1 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.002 | 1 | 1 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.002 | 1 | 1 |
Echinococcus granulosus | terminal deoxycytidyl transferase rev1 | 0.002 | 1 | 1 |
Plasmodium falciparum | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0015 | 0.1934 | 0.5 |
Trypanosoma cruzi | DNA polymerase eta, putative | 0.002 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.002 | 1 | 1 |
Mycobacterium ulcerans | DNA polymerase IV | 0.002 | 1 | 1 |
Echinococcus multilocularis | dna polymerase eta | 0.002 | 1 | 1 |
Schistosoma mansoni | DNA polymerase eta | 0.002 | 1 | 1 |
Echinococcus multilocularis | terminal deoxycytidyl transferase rev1 | 0.002 | 1 | 1 |
Echinococcus granulosus | dna polymerase eta | 0.002 | 1 | 1 |
Entamoeba histolytica | deoxycytidyl transferase, putative | 0.002 | 1 | 1 |
Schistosoma mansoni | rab geranylgeranyl transferase alpha subunit | 0.002 | 1 | 1 |
Trichomonas vaginalis | DNA polymerase IV / kappa, putative | 0.002 | 1 | 1 |
Toxoplasma gondii | exonuclease III APE | 0.0015 | 0.1934 | 0.5 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.002 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.002 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.002 | 1 | 1 |
Echinococcus multilocularis | dna polymerase kappa | 0.002 | 1 | 1 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.002 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.002 | 1 | 1 |
Echinococcus granulosus | dna polymerase kappa | 0.002 | 1 | 1 |
Mycobacterium ulcerans | DNA polymerase IV | 0.002 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.002 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.002 | 1 | 1 |
Trypanosoma brucei | DNA polymerase eta, putative | 0.002 | 1 | 1 |
Schistosoma mansoni | terminal deoxycytidyl transferase | 0.002 | 1 | 1 |
Leishmania major | DNA polymerase eta, putative | 0.002 | 1 | 1 |
Wolbachia endosymbiont of Brugia malayi | exonuclease III | 0.0015 | 0.1934 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.002 | 1 | 1 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.002 | 1 | 1 |
Trypanosoma brucei | unspecified product | 0.002 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Inhibition (functional) | = 99 % | Inhibition of ex vivo platelet aggregation induced by 5 microM Adenosine diphosphate (ADP) 1 hour after oral administration. | ChEMBL. | 9767641 |
Plasma level (ADMET) | = 3.8 uM | Concentration of the compound in plasma 1 hr after oral administration | ChEMBL. | 9767641 |
S | = 106 mg ml-1 | Solubility of the compound in saline. | ChEMBL. | 9767641 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.